CSPC WeiSheng Pharmaceutical (SHIJIAZHUANG) Co., Ltd.
Established in 1997, CSPC WeiSheng Pharmaceutical (SHIJIAZHUANG) Co., Ltd is one of the top China Pharmaceutical companies in terms of comprehensive strength, with total asset USD 3 billion and employee 20000. Turnover USD 3.4 billion in 2015.Continuous 4 years compound growth rate of profit more than 30%. CSPC is the first Chinese pharmaceutical enterprise which is oversea listed in HK stock market (01093.HK), and currently is also the most valuable listed pharmaceutical enterprise in Hong Kong.
CSPC has more than ten affiliates such as Zhongrun Pharma., Weisheng Pharma., Zhongnuo Pharma., Ouyi Pharma., NBP, etc, therein, China Pharmaceutical Group Co., Ltd. – a controlling affiliate established in Hong Kong is the first Chinese pharmaceutical enterprise listed overseas.
CSPC concentrate on the medicine R&D, production and sales. There are thousands of products covering the cardio-cerebrovascular drugs, antibiotics, vitamins, antipyretic analgesic drugs, digestive system drugs, antitumor drugs, and traditional Chinese medicine, etc.
CSPC Pharma. has applied for 200 patents, including more than 10 PCT international patents. Among the rest, the National Class 1 new drug “EBP” with owned intellectual property rights takes the lead in the global market of ischemic cerebral apoplexy therapy, filling a blank of National Class 1 new drug in Hebei Province, and the intellectual property rights thereof are protected in 86 countries around the world.
In terms of quality, CSPC has established a self-contained three-level quality control system, and all the drugs have achieved GMP certification, and all the subordinated companies have passed ISO9000, OHSAS18000 and ISO14001 certifications, and the up-to-standard rate of the products has been kept at 100% constantly in the market. Meanwhile, CSPC has been engaged in improving the quality connotation by technology, and 6 pharmaceutical products (such as caffeine, vitamin C, VB12, amoxicillin, etc.) have achieved COS certification of EU, and obtained a “passport” to the high-end markets in Europe and America.